These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

121 related items for PubMed ID: 8941008

  • 1. Pharmacoeconomic profile of paclitaxel as a first-line treatment for patients with advanced ovarian carcinoma. A lifetime cost-effectiveness analysis.
    Messori A, Trippoli S, Becagli P, Tendi E.
    Cancer; 1996 Dec 01; 78(11):2366-73. PubMed ID: 8941008
    [Abstract] [Full Text] [Related]

  • 2. Is paclitaxel and cisplatin a cost-effective first-line therapy for advance ovarian carcinoma?
    Covens A, Boucher S, Roche K, Macdonald M, Pettitt D, Jolain B, Souetre E, Rivière M.
    Cancer; 1996 May 15; 77(10):2086-91. PubMed ID: 8640674
    [Abstract] [Full Text] [Related]

  • 3. Treatments for newly diagnosed advanced ovarian cancer: analysis of survival data and cost-effectiveness evaluation.
    Messori A, Trippoli S, Becagli P, Tendi E.
    Anticancer Drugs; 1998 Jul 15; 9(6):491-502. PubMed ID: 9877236
    [Abstract] [Full Text] [Related]

  • 4. Cost-utility analysis of paclitaxel in combination with cisplatin for patients with advanced ovarian cancer.
    Ortega A, Dranitsaris G, Sturgeon J, Sutherland H, Oza A.
    Gynecol Oncol; 1997 Sep 15; 66(3):454-63. PubMed ID: 9299261
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Pharmacoeconomic profile of taxanes in advanced ovarian cancer.
    Messori A, Trippoli S.
    Anticancer Drugs; 1998 Nov 15; 9(10):909-16. PubMed ID: 9890702
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Cost-effectivenes of paclitaxel plus cisplatin in advanced non-small-cell lung cancer.
    Earle CC, Evans WK.
    Br J Cancer; 1999 May 15; 80(5-6):815-20. PubMed ID: 10360660
    [Abstract] [Full Text] [Related]

  • 10. The pharmacoeconomics of cancer therapies.
    Bishop JF, Macarounas-Kirchman K.
    Semin Oncol; 1997 Dec 15; 24(6 Suppl 19):S19-106-S19-111. PubMed ID: 9427279
    [Abstract] [Full Text] [Related]

  • 11. Paclitaxel: a pharmacoeconomic review of its use in the treatment of ovarian cancer.
    Young M, Plosker GL.
    Pharmacoeconomics; 2001 Dec 15; 19(12):1227-59. PubMed ID: 11772158
    [Abstract] [Full Text] [Related]

  • 12. Analysis of the cost effectiveness of concurrent cisplatin-based chemoradiation in cervical cancer: implications from five randomized trials.
    Rose PG, Lappas PT.
    Gynecol Oncol; 2000 Jul 15; 78(1):3-6. PubMed ID: 10873400
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Medical therapy of advanced malignant epithelial tumours of the ovary.
    Colombo N, Parma G, Bocciolone L, Franchi D, Sideri M, Maggioni A.
    Forum (Genova); 2000 Jul 15; 10(4):323-32. PubMed ID: 11535983
    [Abstract] [Full Text] [Related]

  • 15. Economic and policy implications of adopting paclitaxel as first-line therapy for advanced ovarian cancer: an Ontario perspective.
    Elit LM, Gafni A, Levine MN.
    J Clin Oncol; 1997 Feb 15; 15(2):632-9. PubMed ID: 9053487
    [Abstract] [Full Text] [Related]

  • 16. Carboplatin/paclitaxel versus cisplatin/paclitaxel as first-line chemotherapy in advanced ovarian cancer: an interim analysis of a randomized phase III trial of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group.
    du Bois A, Lück HJ, Meier W, Möbus V, Costa S, Richter B, Warm M, Bauknecht T, Schröder W, Olbricht S, Nitz U, Jackisch C.
    Semin Oncol; 1997 Oct 15; 24(5 Suppl 15):S15-44-S15-52. PubMed ID: 9346222
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Cost-effectiveness analysis of paclitaxel and cisplatin versus cyclophosphamide and cisplatin as first-line therapy in advanced ovarian cancer. A European perspective.
    Berger K, Fischer T, Szucs TD.
    Eur J Cancer; 1998 Nov 15; 34(12):1894-901. PubMed ID: 10023312
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. From randomised clinical trials to clinical practice : a pragmatic cost-effectiveness analysis of Paclitaxel in first-line therapy for advanced ovarian cancer.
    Limat S, Woronoff-Lemsi MC, Menat C, Madroszyk-Flandin A, Merrouche Y.
    Pharmacoeconomics; 2004 Nov 15; 22(10):633-41. PubMed ID: 15244489
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.